The DOI matches its Crossref record; 276 of the 276 references it cites were found in a registry or an index.
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Open accessAbstract
Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT2 receptor agonists, whereas the indoleamines are relatively non-selective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the characteristic effects of hallucinogens are mediated by interactions with the 5-HT2A receptor. Nevertheless, there is also evidence that interactions with other receptor sites contribute to the psychopharmacological and behavioral effects of the indoleamine hallucinogens. This article reviews the evidence demonstrating that the effects of indoleamine hallucinogens in a variety of animal behavioral paradigms are mediated by both 5-HT2 and non-5-HT2 receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pazos, A., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“The majority of this clinical work has focused on psilocybin (Vollenweider et al., 1997; Gouzoulis-Mayfrank et al., 1999; Moreno et al., 2006; Griffiths et al., 2006; Grob et al., 2011), althoughmescaline (Hermle et al., 1992, 1998) and DMT (Strassman and Qualls, 1994; Strassman et al., 1994;…”
BackgroundPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
PEROUTKA, S. J., & SNYDER, S. H. (1979) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13812-1 · Cited by 1,360
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 2×
“Studies have also examined whether psilocybin is effective at reducing symptoms in patients with obsessive-compulsive disorder (OCD) (Moreno et al., 2006), and anxiety in terminal cancer patients (Grob et al., 2011).”
BackgroundSelf-citationLeysen, J. E., Niemegeers, C. J., Van Nueten, J. M., & Laduron, P. M. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14623-3 · Cited by 1,071
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Regulation of serotonin-2C receptor G-protein coupling by RNA editing
Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., & Emeson, R. B. (1997) · Nature · doi:10.1038/387303a0 · Cited by 1,010 · cited 1×
“Editing of 5-HT2C receptor mRNA can dramatically alter G-protein coupling (Burns et al., 1997), and thus differences in 5-HT2C editing could potentially alter how 5-HT2A and 5-HT2C receptors interact in different strains of mice.”
BackgroundGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“Importantly, recent clinical trials with the selective 5- HT2C agonist lorcaserin for weight loss have shown that this compound does not produce any hallucinogen-like effects (Smith et al., 2009, 2010).”
BackgroundElectrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 845
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 4×
“The majority of this clinical work has focused on psilocybin (Vollenweider et al., 1997; Gouzoulis-Mayfrank et al., 1999; Moreno et al., 2006; Griffiths et al., 2006; Grob et al., 2011), althoughmescaline (Hermle et al., 1992, 1998) and DMT (Strassman and Qualls, 1994; Strassman et al., 1994;…”
BackgroundInfluentialThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Pompeiano, M., Palacios, J., & Mengod, G. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00440.1992 · Cited by 698
Tricklebank, M. D., Forler, C., & Fozard, J. R. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90714-3 · Cited by 675
Shulgin, A. T., & Shulgin, A. (1991) · Cited by 668
Grahame‐Smith, D. G. (1971) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1971.tb12034.x · Cited by 665
Two Distinct Central Serotonin Receptors with Different Physiological Functions
Peroutka, S. J., Lebovitz, R. M., & Snyder, S. H. (1981) · Science · doi:10.1126/science.7221567 · Cited by 637
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS
Woolley, D. W., & Shaw, E. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.4.228 · Cited by 602
Pazos, A., Hoyer, D., & Palacios, J. M. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90057-8 · Cited by 596
Functional Correlates of Serotonin 5-HT1Recognition Sites
Hoyer, D. (1988) · Journal of Receptor Research · doi:10.3109/10799898809048978 · Cited by 562
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535 · cited 2×
“It has been reported that DMT is a s1 receptor agonist with moderate affinity (KD1⁄4 14.75 mM; Fontanilla et al., 2009); however, it is not clear whether this interaction contributes to the effects of DMT because the affinity of the drug for 5-HT1A and 5-HT2A receptors is w2-orders of magnitude greater than for s1 bin…”
BackgroundInfluentialHjorth, S., Carlsson, A., Lindberg, P., Sanchez, D., Wikstr�m, H., Arvidsson, L. E., Hacksell, U., & Nilsson, J. L. G. (1982) · Journal of Neural Transmission · doi:10.1007/bf01276574 · Cited by 515
Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.-A., & Newman-Tancredi, A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039867 · Cited by 484
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 2×
“The majority of this clinical work has focused on psilocybin (Vollenweider et al., 1997; Gouzoulis-Mayfrank et al., 1999; Moreno et al., 2006; Griffiths et al., 2006; Grob et al., 2011), althoughmescaline (Hermle et al., 1992, 1998) and DMT (Strassman and Qualls, 1994; Strassman et al., 1994;…”
BackgroundSerotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
Self-citationDe Vivo, M., & Maayani, S. (1986) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24854-6 · Cited by 424
Lysergic acid diethylamide: Sensitive neuronal units in the midbrain raphe
Aghajanian, G. K., Foote, W. E., & Sheard, M. H. (1968) · Science · doi:10.1126/science.161.3842.706 · Cited by 404 · cited 1×
“In 1968, Aghajanian and colleagues found that intravenous LSD (10e20 mg/kg) completely inhibits the firing of serotonergic neurons in the dorsal (DRN) and median (MRN) raphe nuclei in rats (Aghajanian et al., 1970, 1968).”
BackgroundVerge, D., Daval, G., Patey, A., Gozlan, H., El Mestikawy, S., & Hamon, M. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90099-8 · Cited by 384
A METHOD FOR ASSESSING THE EFFECTS OF DRUGS ON THE CENTRAL ACTIONS OF 5‐HYDROXYTRYPTAMINE
CORNE, S. J., PICKERING, R. W., & WARNER, B. T. (1963) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1963.tb01302.x · Cited by 380
Porter, R. H. P., Benwell, K. R., Lamb, H., Malcolm, C. S., Allen, N. H., Revell, D. F., Adams, D. R., & Sheardown, M. J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702751 · Cited by 358
Drug discrimination and state dependent learning
Ho, B. T., Chute, D. L., & Richards, D. W. (1978) · Academic Press eBooks · Cited by 350
Peroutka, S. J. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb04532.x · Cited by 344
Titeler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343
BEDARD, P., & PYCOCK, C. (1977) · Neuropharmacology · doi:10.1016/0028-3908(77)90117-4 · Cited by 336
5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential
Martin, J. R., Bös, M., Jenck, F., Moreau, J.-L., Mutel, V., Sleight, A. J., Wichmann, J., Andrews, J. S., Berendsen, H. H. G., Broekkamp, C. L. E., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37669-4 · Cited by 334
Haigler, H. J., & Aghajanian, G. K. (1974) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29794-4 · Cited by 320
ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS
AGHAJANIAN, G. K., FOOTE, W. E., & SHEARD, M. H. (1970) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28462-2 · Cited by 309
Lucki, I., Nobler, M. S., & Frazer, A. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21483-5 · Cited by 305
Schreiber, R., Brocco, M., Audinot, V, Gobert, A., Veiga, S., & Millan, M. J. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09485-6 · Cited by 300
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Nagai, F., Nonaka, R., & Satoh Hisashi Kamimura, K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.075 · Cited by 279
A possible correlation between drug-induced hallucinations in man and a behavioural response in mice
Corne, S. J., & Pickering, R. W. (1967) · Psychopharmacologia · doi:10.1007/bf00401509 · Cited by 271
Neuropharmacology of Serotonin
(1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90276-8 · Cited by 267
Human psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261 · cited 2×
“There is also evidence that 5-HT1 receptor activation by indoleamines acts to suppress expression of HTR, ESR, and other 5-HT2A-mediated behavioral effects, a conclusion that is supported by some clinical data (Strassman, 1996).”
BackgroundResultThe Botany and Chemistry of Hallucinogens
Reynolds, T., Schultes, R. E., & Hofmann, A. (1974) · Kew Bulletin · doi:10.2307/4108565 · Cited by 255
Willins, D. L., & Meltzer, H. Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36840-5 · Cited by 245
Do functional relationships exist between 5-HT1A and 5-HT2 receptors?
Darmani, N. A., Martin, B. R., Pandey, U., & Glennon, R. A. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90098-3 · Cited by 244
Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome
Smith, L. M., & Peroutka, S. J. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90477-6 · Cited by 242
Molecular pharmacology and biology of 5-HT1C receptors
Hoyer, D. (1988) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(88)90174-5 · Cited by 236
Handbook of the Behavioral Neurobiology of Serotonin
(2010) · Handbook of Behavioral Neuroscience · doi:10.1016/c2009-0-01827-3 · Cited by 233
VanderMaelen, C. P., Matheson, G. K., Wilderman, R. C., & Patterson, L. A. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90343-2 · Cited by 233
Varty, G. B., Higgins, G. A., & Higgins, G. A. (1995) · Psychopharmacology · doi:10.1007/bf02246437 · Cited by 231
Carter, O. L., Burr, D. C., Pettigrew, J. D., Wallis, G. M., Hasler, F., & Vollenweider, F. X. (2005) · Journal of Cognitive Neuroscience · doi:10.1162/089892905774597191 · Cited by 230
Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses
Geyer, M. A., Russo, P. V., & Masten, V. L. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90266-2 · Cited by 214
Self-citationHalberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388326 · Cited by 213
Self-citationLisuride and Other Dopamine Agonists
Godwin-Austen, R. B. (1983) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.46.10.967 · Cited by 199
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K.-A. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-916185 · Cited by 198
The Botany and Chemistry of Hallucinogens.
Lipp, F. J., Schultes, R. E., & Hofmann, A. (1981) · Brittonia · doi:10.2307/2806315 · Cited by 193
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
Mckenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 192
Lorcaserin (APD356), a Selective 5‐HT2CAgonist, Reduces Body Weight in Obese Men and Women
Smith, S. R., Prosser, W. A., Donahue, D. J., Morgan, M. E., Anderson, C. M., Shanahan, W. R., & APD356‐004 Study Group (2009) · Obesity · doi:10.1038/oby.2008.537 · Cited by 192
Callaway, C. W., Wing, L. L., & Geyer, M. A. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12637-2 · Cited by 192
Self-citationGlennon, R. A., Young, R., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90464-8 · Cited by 190 · cited 4×
“Based on these findings, Glennon and colleagues (Glennon et al., 1983b) proposed that the stimulus effects of hallucinogenic drugs aremediated by the 5-HT2A receptor.”
BackgroundInfluentialVollenweider, F. X., Csomor, P. A., Knappe, B., Geyer, M. A., & Quednow, B. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301324 · Cited by 190
Self-citationTransduction Mechanisms of Drug Stimuli
Colpaert, F. C., & Balster, R. L. (1988) · Springer eBooks · doi:10.1007/978-3-642-73223-2 · Cited by 188
Romero, L. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00240-e · Cited by 185
Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats
Sipes, T. A., & Geyer, M. A. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90074-4 · Cited by 184
Self-citationHermle, L., Fünfgeld, M., Oepen, G., Botsch, H., Borchardt, D., Gouzoulis, E., Fehrenbach, R. A., & Spitzer, M. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90059-9 · Cited by 182
5-HT2A and 5-HT2C Receptors Exert Opposing Effects on Locomotor Activity in Mice
Halberstadt, A. L., van der Heijden, I., Ruderman, M. A., Risbrough, V. B., Gingrich, J. A., Geyer, M. A., & Powell, S. B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.29 · Cited by 176
Self-citationde Montigny, C., & Aghajanian, G. K. (1977) · Neuropharmacology · doi:10.1016/0028-3908(77)90142-3 · Cited by 171
DEMONTIGNY, C. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90095-9 · Cited by 170
Serotonin; From cell biology to pharmacology and therapeutics
(1991) · International Journal of Biochemistry · doi:10.1016/0020-711x(91)90208-5 · Cited by 169
Hensler, J. G., Kovachich, G. B., & Frazer, A. (1991) · PubMed · Cited by 168
Colpaert, F. C., Niemegeers, C. J., & Janssen, P. A. (1982) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33038-7 · Cited by 167
Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Daley, P. F., & Ruoho, A. E. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0308-8 · Cited by 162
Effects of apomorphine and amphetamine on patterns of locomotor and investigatory behavior in rats
Geyer, M. A., Russo, P. V., Segal, D. S., & Kuczenski, R. (1987) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(87)90460-6 · Cited by 161
Self-citationSelective activation of 5HT1A receptors induces lower lip retraction in the rat
Berendsen, H. H. G., Jenck, F., & Broekkamp, C. L. E. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90477-2 · Cited by 161
Yagaloff, K., & Hartig, P. (1985) · The Journal of Neuroscience · doi:10.1523/jneurosci.05-12-03178.1985 · Cited by 160
Gouzoulis‐Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H. J., Kovar, K. ‐., Lindenblatt, H., Hermle, L., Spitzer, M., & Sass, H. (1999) · Psychopharmacology · doi:10.1007/s002130050860 · Cited by 157
Dumuis, A., Sebben, M., & Bockaert, J. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13142-8 · Cited by 155
Sanders‐Bush, E., Burris, K. D., & Knoth, K. M. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22189-9 · Cited by 154
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
Pierce, P. A., & Peroutka, S. J. (1989) · Psychopharmacology · doi:10.1007/bf00443425 · Cited by 152
Johansson, C., Jackson, D. M., Zhang, J., & Svensson, L. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00160-x · Cited by 148
Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors
Smith, R. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00110-5 · Cited by 147
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0930-9 · Cited by 146
Marquis, K. L., Sabb, A. L., Logue, S. F., Brennan, J. A., Piesla, M. J., Comery, T. A., Grauer, S. M., Ashby, C. R., Nguyen, H. Q., Dawson, L. A., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106989 · Cited by 146
2,5-Dimethoxy-4-methyl-amphetamine (STP): A New Hallucinogenic Drug
Snyder, S. H., Faillace, L. A., & Hollister, L. E. (1967) · Science · doi:10.1126/science.158.3801.669 · Cited by 146
Mengod, G., Vilaró, M. T., Raurich, A., López‐Giménez, J. F., Cortés, R., & Palacios, J. M. (1996) · The Histochemical Journal · doi:10.1007/bf02272148 · Cited by 145
Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI
Arnt, J., & Hyttel, J. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90178-7 · Cited by 145
Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats
Fantegrossi, W. E., Harrington, A. W., Kiessel, C. L., Eckler, J. R., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.12.015 · Cited by 145
Colpaert, F. C., Meert, T. F., Niemegeers, C. J. E., & Janssen, P. A. J. (1985) · Psychopharmacology · doi:10.1007/bf00431683 · Cited by 144
la Cour, C. M., Mestikawy, S. E., Hanoun, N., Hamon, M., & Lanfumey, L. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022756 · Cited by 144
Specificity of a rat behavioral model for serotonin receptor activation.
Sloviter, R. S., Drust, E. G., & Connor, J. D. (1978) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31333-9 · Cited by 141
Tricklebank, M. D., Forler, C., Middlemiss, D. N., & Fozard, J. R. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90467-4 · Cited by 141
Comparison of the reactions induced by psilocybin and LSD-25 in man
Isbell, H. (1959) · Psychopharmacology · doi:10.1007/bf00408109 · Cited by 140
Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives
Jenner, P. G. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.4.392 · Cited by 139
Nelson, D. L. G., Lucaites, V. L., Wainscott, D. B., & Glennon, R. A. (1999) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005315 · Cited by 139
Cross tolerance between LSD and psilocybin
Isbell, H., Wolbach, A. B., Wikler, A., & Miner, E. J. (1961) · Psychopharmacologia · doi:10.1007/bf00407974 · Cited by 137
Fiorella, D. J., Rabin, R. A., & Winter, J. C. (1995) · Psychopharmacology · doi:10.1007/bf02246074 · Cited by 137
Do classical hallucinogens act as 5-HT2 agonists or antagonists?
Glennon, R. A. (1990) · PubMed · Cited by 136
Neuropharmacology of serotonin
Straughan, D. W. (1986) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(86)90240-3 · Cited by 134
Marona‐Lewicka, D., Thisted, R. A., & Nichols, D. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2183-9 · Cited by 134
Sadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., Jan, C.-R., & Titeler, M. (1989) · Psychopharmacology · doi:10.1007/bf00441948 · Cited by 132
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131 · cited 4×
“By contrast, indolealkylamines are relatively non-selective for 5-HT receptors, displaying moderate to high affinity for 5-HT1 and 5-HT2 subtypes (Pierce and Peroutka, 1989; McKenna et al., 1990; Deliganis et al., 1991; Blair et al., 2000).”
BackgroundInfluentialBehavioral Pharmacology of 5-ht
Bevan, P., & Bevan, P. (2013) · Psychology Press eBooks · doi:10.4324/9780203771310 · Cited by 130
Schreiber, R., Brocco, M., & Millan, M. J. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90643-2 · Cited by 130
Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination.
Winter, J. C., & Rabin, R. A. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10401-1 · Cited by 129
Fantegrossi, W. E., Simoneau, J., Cohen, M. S., Zimmerman, S. M., Henson, C., Rice, K. C., & Woods, J. H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172247 · Cited by 128
Comparison of psilocin with psilocybin, mescaline and LSD-25
Wolbach, A. B., Miner, E. J., & Isbell, H. (1962) · Psychopharmacology · doi:10.1007/bf00412109 · Cited by 126
5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex.
Rigdon, G. C., & Weatherspoon, J. K. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10375-3 · Cited by 126
Agonist activity of LSD and lisuride at cloned 5HT 2A and 5HT 2C receptors
Egan, C. T., Herrick‐Davis, K., Miller, K. J., Glennon, R. A., & Teitler, M. (1998) · Psychopharmacology · doi:10.1007/s002130050585 · Cited by 125
Canal, C. E., da Silva, U., Gresch, P. J., Watt, E. E., Sanders‐Bush, E., & Airey, D. C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1784-0 · Cited by 122
DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum
Sipes, T. E., & Geyer, M. A. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00316-8 · Cited by 119
Self-citationSipes, T. E., & Geyer, M. A. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199512000-00010 · Cited by 117
Self-citationMcLean, T. H., Parrish, J. C., Braden, M. R., Marona‐Lewicka, D., Gallardo‐Godoy, A., & Nichols, D. E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060656o · Cited by 117
Ouagazzal, A., Grottick, A. J., Moreau, J., & Higgins, G. A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00282-2 · Cited by 116
Transduction Mechanisms of Drug Stimuli
Colpaert, F. C., Balster, R. L., & Dependency, S. (1988) · Medical Entomology and Zoology · Cited by 114
Gold, L. H., Koob, G. F., & Geyer, M. A. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13399-5 · Cited by 114
Self-citationGlennon, R. A., Raghupathi, R., Bartyzel, P., Teitler, M., & Leonhardt, S. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00082a014 · Cited by 113
Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists
Vickers, S. P., Easton, N., Malcolm, C., Allen, N. H., Porter, R. H., Bickerdike, M. J., & Kennett, G. A. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00552-4 · Cited by 113
Tricklebank, M. D., Neill, J. C., Kidd, E. J., & Fozard, J. R. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90204-4 · Cited by 111
Ralph, R. J., Masten, V. L., Otero-Corchón, V., Low, M. J., & Geyer, M. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09604.2002 · Cited by 111
Self-citationMeasuring movement and locomotion : from invertebrates to humans
Ossenkopp, K., Kavaliers, M., & Sanberg, P. R. (1996) · Cited by 109
Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli
Hirschhorn, I. D., & Winter, J. C. (1971) · Psychopharmacology · doi:10.1007/bf00401468 · Cited by 109
Mescaline and LSD: Direct and indirect effects on serotonin-containing neurons in brain
Haigler, H. J., & Aghajanian, G. K. (1973) · European Journal of Pharmacology · doi:10.1016/0014-2999(73)90206-9 · Cited by 109
5HT-2 mediation of acute behavioral effects of hallucinogens in rats
Wing, L. L., Tapson, G. S., & Geyer, M. A. (1990) · Psychopharmacology · doi:10.1007/bf02244617 · Cited by 107
Self-citationYocca, F. D., Iben, L. G., & Meller, E. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09248-x · Cited by 107
The serotonin 5-HT2A receptor agonist TCB-2: a behavioral and neurophysiological analysis
Fox, M. A., French, H. T., LaPorte, J. L., Blackler, A. R., & Murphy, D. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1694-1 · Cited by 106
Cross tolerance between mescaline and LSD-25 with a comparison of the mescaline and LSD reactions
Wolbach, A. B., Isbell, H., & Miner, E. J. (1962) · Psychopharmacology · doi:10.1007/bf00413101 · Cited by 105
Drug-induced penile erections in rats: indications of serotonin1B receptor mediation
Berendsen, H. H. G., & Broekkamp, C. L. E. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90676-5 · Cited by 105
Detection and Characterization of the Serotonin 5‐HT1D Receptor in Rat and Human Brain
Herrick‐Davis, K., & Titeler, M. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb03052.x · Cited by 104
Sipes, T. E., & Geyer, M. A. (1995) · Psychopharmacology · doi:10.1007/bf02245096 · Cited by 103
Self-citationRapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment
Leysen, J. E., Janssen, P. F. M., & Niemegeers, C. J. E. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90409-3 · Cited by 103
Risbrough, V. B., Masten, V. L., Caldwell, S., Paulus, M. P., Low, M. J., & Geyer, M. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301161 · Cited by 102
Self-citation(1975) · PubMed · Cited by 101
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995) · Psychopharmacology · doi:10.1007/bf02245940 · Cited by 100
Glennon, R. A., Seggel, M. R., Soine, W. H., Herrick‐Davis, K., Lyon, R. A., & Titeler, M. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00396a003 · Cited by 100
Krebs-Thomson, K., Ruiz, E. M., Masten, V. L., Buell, M. R., & Geyer, M. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0566-1 · Cited by 97
Self-citationSerotonin1B Receptor Activation Mimics Behavioral Effects of Presynaptic Serotonin Release
Rempel-Clower, N., Callaway, C. W., & Geyer, M. A. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.22 · Cited by 91
Self-citationNichols, D. E., Frescas, S. P., Marona‐Lewicka, D., & Kurrasch‐Orbaugh, D. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020153s · Cited by 91
Glennon, R. A., Rosecrans, J. A., & Young, R. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030305 · Cited by 89
Cox, R. F., Meller, E., & Waszczak, B. L. (1993) · Synapse · doi:10.1002/syn.890140407 · Cited by 87
Krebs-Thomson, K. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00164-4 · Cited by 87
Psilocybin-induced stimulus control in the rat
Winter, J. C., Rice, K. C., Amorosi, D. J., & Rabin, R. A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.003 · Cited by 86
MCKENNA, D. (1989) · Neuropsychopharmacology · doi:10.1016/0893-133x(89)90010-9 · Cited by 86
Seeman, P. M., Guan, H., & Hirbec, H. (2009) · Synapse · doi:10.1002/syn.20647 · Cited by 85
A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA
Gold, L. H., Hubner, C. B., & Koob, G. F. (1989) · Psychopharmacology · doi:10.1007/bf00634450 · Cited by 84
Fornal, C. A., Litto, W. J., Metzler, C. W., Marrosu, F., Tada, K., & Jacobs, B. L. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22545-9 · Cited by 84
Gallager, D. W., & Aghajanian, G. K. (1975) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30200-4 · Cited by 83
Screening hallucinogenic drugs: Systematic study of three behavioral tests
Silva, M. T. A., & Calil, H. M. (1975) · Psychopharmacology · doi:10.1007/bf00429548 · Cited by 82
Pauwels, P. J., Gompel, P. V., & Leysen, J. E. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90073-6 · Cited by 82
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
Halberstadt, A. L., & Geyer, M. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1718-x · Cited by 81
Self-citationBuckholtz, N. S., Zhou, D.-F., Freedman, D. X., & Potter, W. Z. (1990) · PubMed · Cited by 80
Knockout Mice Reveal Opposite Roles for Serotonin 1A and 1B Receptors in Prepulse Inhibition
Dulawa, S. C. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00164-5 · Cited by 80
Gouzoulis‐Mayfrank, E., Heekeren, K., Thelen, B., Lindenblatt, H., Kovar, K. ‐., Sass, H., & Geyer, M. A. (1998) · Behavioural Pharmacology · doi:10.1097/00008877-199811000-00011 · Cited by 80
Self-citationWinter, J. C., Eckler, J. R., & Rabin, R. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1636-2 · Cited by 79
The Paradox of 5-Methoxy-N,N-Dimethyltryptamine
Winter, J. C., Filipink, R. A., Timineri, D. M., Helsley, S., & Rabin, R. A. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00178-1 · Cited by 79
Riba, J., Rodríguez‐Fornells, A., & Barbanoj, M. J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1237-5 · Cited by 79
Response of central monoaminergic neurons to lisuride: Comparison with LSD
Rogawski, M. A., & Aghajanian, G. K. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90148-6 · Cited by 78
Fletcher, P. J., Tampakeras, M., Sinyard, J., Slassi, A., Isaac, M. B., & Higgins, G. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.05.011 · Cited by 76
5-HT2C receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice
Hackler, E., Airey, D. C., Shannon, C. C., Sodhi, M., & Sanders‐Bush, E. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.02.005 · Cited by 75
Acquired and Crossed Tolerance to Mescaline, LSD-25, and BOL-148
Balestrieri, A., & FONTANARI, D. (1959) · Archives of General Psychiatry · doi:10.1001/archpsyc.1959.03590030063008 · Cited by 74
Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats
Fantegrossi, W. E., Harrington, A. W., Eckler, J. R., Arshad, S., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0009-4 · Cited by 74
Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors
Deliganis, A. V., Pierce, P. A., & Peroutka, S. J. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90178-8 · Cited by 73
Fiorella, D. J., Rabin, R. A., & Winter, J. C. (1995) · Psychopharmacology · doi:10.1007/bf02246075 · Cited by 73
Kleven, M. S., Assié, M., & Koek, W. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36843-0 · Cited by 73
Fantegrossi, W. E., Reissig, C. J., KATZ, E., Yarosh, H. L., Rice, K. C., & WINTER, J. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.09.007 · Cited by 72
Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats
Meert, T. F., Haes, P. D., & Janssen, P. A. J. (1989) · Psychopharmacology · doi:10.1007/bf00442251 · Cited by 72
Paulus, M. P., & Geyer, M. A. (1992) · PubMed · Cited by 71
Self-citationA Novel (Benzodifuranyl)aminoalkane with Extremely Potent Activity at the 5-HT2A Receptor
Parker, M. A., Marona‐Lewicka, D., Lucaites, V. L., Nelson, D. L. G., & Nichols, D. E. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9803525 · Cited by 70
The discriminative stimulus properties of LSD: Mechanisms of action☆
KUHN, D., WHITE, F., & Appel, J. B. (1978) · Neuropharmacology · doi:10.1016/0028-3908(78)90109-0 · Cited by 70
Differential Effect of Gepirone on Presynaptic and Postsynaptic Serotonin Receptors
Blier, P. U., & de Montigny, C. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199006001-00004 · Cited by 70
Spencer, D. G., Gläser, T., & Traber, J. (1987) · Psychopharmacology · doi:10.1007/bf00179927 · Cited by 69
Lysergic Acid Diethylamide (LSD) and Lisuride: Differentiation of Their Neuropharmacological Actions
White, F. J., & Appel, J. B. (1982) · Science · doi:10.1126/science.7071600 · Cited by 69
Marona‐Lewicka, D., & Nichols, D. E. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.001 · Cited by 69
A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats.
Adams, L. M., & Geyer, M. A. (1985) · Behavioral Neuroscience · doi:10.1037//0735-7044.99.5.881 · Cited by 68
Self-citationGlennon, R. A., Dukat, M., El-Bermawy, M., Law, H., De Los Angeles, J., Teitler, M., King, A., & Herrick-Davis, K. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00039a004 · Cited by 67
Mosko, S. S., & Jacobs, B. L. (1977) · Brain Research · doi:10.1016/0006-8993(77)90312-2 · Cited by 67
Serotonin, sleep and mental disorder
Idzikowski, C., & Cowen, P. J. (1991) · Medical Entomology and Zoology · Cited by 66
Observations on direct and cross tolerance with LSD and d-amphetamine in man
Rosenberg, D. E., Wolbach, A. B., Miner, E. J., & Isbell, H. (1963) · Psychopharmacology · doi:10.1007/bf00405570 · Cited by 64
Smith, R. L., Barrett, R. J., & Sanders‐Bush, E. (1999) · Psychopharmacology · doi:10.1007/s002130051000 · Cited by 62
Characterization of the Discriminative Stimulus Properties Induced by 5‐HT1and 5‐HT2Agonists in Rats
Arnt, J. (1989) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1989.tb00623.x · Cited by 62
The 5-HT1A receptor and the stimulus effects of LSD in the rat
Reissig, C. J., Eckler, J. R., Rabin, R. A., & Winter, J. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0068-6 · Cited by 62
Burris, K. D., Breeding, M., & Sanders‐Bush, E. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20333-0 · Cited by 62
Gaps and peculiarities in 5-HT2 receptor studies.
(1990) · PubMed · Cited by 62
Páleníček, T., Balíková, M., Bubeníková-Valešová, V., & Horáček, J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-0926-5 · Cited by 61
Glennon, R. A. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90243-1 · Cited by 61
The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide
Rosenberg, D. E., Isbell, H., Miner, E. J., & Logan, C. R. (1964) · Psychopharmacology · doi:10.1007/bf00413244 · Cited by 61
Delirium: a subcortical phenomenon?
Trzepacz, P. T., Sclabassi, R. J., & Thiel, D. H. V. (1989) · Journal of Neuropsychiatry · doi:10.1176/jnp.1.3.283 · Cited by 61
Marona‐Lewicka, D., Kurrasch‐Orbaugh, D. M., Selken, J., Cumbay, M. G., Lisnicchia, J., & Nichols, D. E. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1141-z · Cited by 60
Hallucinogens, neurochemical, behavioral, and clinical perspectives
Jacobs, B. L. (1984) · Raven Press eBooks · Cited by 59
Bakshi, V. P., Tricklebank, M. D., Neijt, H. C., Masten, V. L., & Geyer, M. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38001-2 · Cited by 59
Self-citationMittman, S. M., & Geyer, M. A. (1989) · Psychopharmacology · doi:10.1007/bf00451682 · Cited by 59
Self-citationDoherty, J. M., Masten, V. L., Powell, S. B., Ralph, R. J., Klamer, D., Low, M. J., & Geyer, M. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301657 · Cited by 59
Self-citationDaily LSD administration selectively decreases serotonin2 receptor binding in rat brain
Buckholtz, N. S., Freedman, D. X., & Middaugh, L. D. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90407-8 · Cited by 58
Clinical Effectiveness of Lisuride Hydrogen Maleate: A Double‐Blind Trial Versus Methysergide
Herrmann, W. M., HOROWSKI, R., Dannehl, K., Kramer, U., & Lurati, K. (1977) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1977.hed1702054.x · Cited by 58
A characteristic effect of hallucinogens on investigatory responding in rats
Geyer, M. A., Light, R. K., Rose, G. J., Petersen, L. R., Horwitt, D. D., Adams, L. M., & Hawkins, R. L. (1979) · Psychopharmacology · doi:10.1007/bf00491975 · Cited by 57
Self-citation
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Broadband Cortical Desynchronization Underlies the Human Psychedelic State
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K. D., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2063-13.2013 · Cited by 475
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456
Metadata
- Authors
- Halberstadt, A. L., & Geyer, M. A.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 61
- Issue
- 3
- Pages
- 364-381
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2080123927
- Cited by
- 411
- References
- 276
- FWCI
- 15.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.